Characterization of Alpelisib in Rat Plasma by a Newly Developed UPLC-MS/MS Method: Application to a Drug-Drug Interaction Study

Alpelisib, an oral selective and small-molecule phosphoinositide 3-kinase inhibitor, was lately approved in the United States to treat breast cancer. A sensitive method to quantify alpelisib levels in rat plasma on the basis of ultra-performance liquid chromatography–tandem mass spectrometry techniq...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Qiong, Lan, Xia, Zhao, Zhuofei, Su, Xiaohang, Zhang, Yuji, Zhou, Xiao-Yang, Xu, Ren-Ai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656162/
https://www.ncbi.nlm.nih.gov/pubmed/34899297
http://dx.doi.org/10.3389/fphar.2021.743411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656162/
https://www.ncbi.nlm.nih.gov/pubmed/34899297
http://dx.doi.org/10.3389/fphar.2021.743411

Ejemplares similares